Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Kidney Disease and beyond
SGLT2is play a crucial role in the management of DKD and HF by addressing multiple pathogenic pathways. Currently, SGLT2is are included in clinical guidelines for DKD and HF management, and their benefits extend to nondiabetic populations. Further research is needed to explore SGLT2is' multifaceted mechanisms and potential applications across diverse patient populations and different disease etiologies.
Authors
- C. Elena Cervantes (ORCID: https://orcid.org/0000-0002-7161-382X)
- Mohamad Hanouneh
- Mohamed G. Atta (ORCID: https://orcid.org/0000-0001-7572-9961)
- Zein Alabdin Hannouneh (ORCID: https://orcid.org/0000-0002-4516-9526)
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Al Andalus University (SY)
- Nephrology Center of Maryland (US)
Publication Details
- Journal
- Glomerular Diseases
- Published
- 2025-01-23
- DOI
- https://doi.org/10.1159/000543685
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29